Risedronic acid is a bisphosphonate clinically used to strengthen bone; it exhibits anti-osteoporotic, anti-inflammatory, antinociceptive, anti-parasitic, and antibiotic activities. Risedronic acid inhibits bone marrow adipogenesis and suppresses RANKL expression in vivo. In vivo, risedronic acid displays antimalarial activity, inhibiting the transfer of farnesyl phosphate to Plasmodium proteins and preventing parasitic growth in vivo. Additionally, risedronic acid inhibits release of TNF-α and leukotriene B4 (LTB4), decreasing inflammatory cell infiltration in vivo. In other animal models, risedronic acid inhibits chemically-induced pain.